Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

Conditions

Cancer, Cancer Risk

Brief summary

The overall objective of this study is to ultimately develop an improved standard of cancer care by facilitating new cancer research, clinical trials, new technology, new informatics solutions, and personalized medicine for the University of New Mexico Comprehensive Cancer Center (UNMCCC) and the Oncology Research Information Exchange Network (ORIEN) Consortium of academic medical centers, community hospital systems, and other health care providers. To bring new translational research to the community, the ORIEN consortium has initiated the ORIEN Total Cancer Care Program (TCCP). The TCCP establishes a unique collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from thousands of patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.

Detailed description

Through this protocol, UNMCCC and its partners will establish and maintain a unique repository of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected from thousands of patients 18 years of age or older who have cancer or are at risk of developing cancer. In this protocol, the investigators require the permission of patients to study their answers to survey questions that may be collected as part of their regular clinical care, permission to study their medical and related records, and permission to collect excess tissues removed at the time of planned surgery, an additional tumor sampling (needle passes) at the time of planned diagnostic biopsies, previously collected, stored tumor tissue (if available), blood, and/or other biological samples. Additional research tumor samples may be collected at the time of any diagnostic needle biopsy or endoscopic biopsy or, if available, patient tissue from a previous procedure will be obtained and utilized as needed. Clinical and related data will be collected on all patients from the time of initial entry into the study and will continue for life.

Dipankor Chatterjee, Dennis J. Grencewicz, Alexander Loncar, Ruohan Wu, Alex Samouilov et al. (40 authors)

Cancer Research2026-04-03

10.1158/1538-7445.am2026-63

Abstract B020: Unveiling the tumor-associated microbiome in ovarian cancer: Correlations with clinical features, outcomes, and treatment strategies

Yogita Mehra, Rebecca Hoyd, Daniel Spakowicz, Aik Choon Tan, Thèrése Bocklage et al. (22 authors)

Cancer Research2025-09-19

10.1158/1538-7445.ovarian25-b020

Differential Infiltration of Key Immune T-Cell Populations Across Malignancies Varying by Immunogenic Potential and the Likelihood of Response to Immunotherapy

Islam Eljilany, Sam Coleman, Aik Choon Tan, Martin D. McCarter, John D. Carpten et al. (22 authors)

Cells2024-12-032 citations

10.3390/cells13231993

Differences in Co-Expression of T Cell Co-Inhibitory and Co-Stimulatory Molecules with PD-1 Across Different Human Cancers.

Tarhini AA, Hedges D, Tan AC, Rodriguez P, Sukrithan V, Ratan A, McCarter MD, Carpten J, Colman H, Ikeguchi AP, Puzanov I, Arnold SM, Churchman ML, Hwu P, Conejo-Garcia JR, Dalton WS, Weiner GJ, Eljilany I.

2024-06-101 citations

10.29011/2574-710x.10224

A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits.

Ahmad A. Tarhini, Tingyi Li, Sandra J. Lee, Islam Eljilany, William A. LaFramboise et al. (20 authors)

Journal of Clinical Oncology2024-06-01

10.1200/jco.2024.42.16_suppl.9568

Abstract 71: Differential infiltration of key immune cell populations across malignancies varying by immunogenic potential and likelihood of response to immunotherapy

Ahmad A. Tarhini, Islam Eljilany, Sam Coleman, Dale J. Hedges, Martin D. McCarter et al. (17 authors)

Cancer Research2024-03-22

10.1158/1538-7445.am2024-71

Abstract 3886: Analysis of clonal heterogeneity within paired primary and metastatic tumor samples of patients with solid tumors and implications for neoantigen-based personalized cancer vaccines

Alyssa Obermayer, Timothy I. Shaw, Darwin Chang, Joshua S. Davis, Jamie K. Teer et al. (25 authors)

Cancer Research2024-03-22

10.1158/1538-7445.am2024-3886

151 Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines

Timothy I. Shaw, Darwin Chang, Alyssa Obermayer, Jamie K. Teer, Xiaoqing Yu et al. (23 authors)

Regular and Young Investigator Award Abstracts2023-10-31

10.1136/jitc-2023-sitc2023.0151

185 Global and local copy number aberration signatures as prognostic and immunotherapeutic predictors

Xuefeng Wang, Tingyi Li, Timothy I. Shaw, Sijie Yao, Islam Eljilany et al. (18 authors)

Regular and Young Investigator Award Abstracts2023-10-31

10.1136/jitc-2023-sitc2023.0185

898 Demonstration of the utility of real-world progression-free survival (rwPFS) by application of an IFN-γ-related signature in a real-world cohort of patients with melanoma

Michael D. Radmacher, Phaedra Agius, Oliver Hampton, David McKean, Daniel R Elgort et al. (24 authors)

Regular and Young Investigator Award Abstracts2023-10-31

10.1136/jitc-2023-sitc2023.0898

The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors

Islam Eljilany, Payman Ghasemi Saghand, James L. Chen, Aakrosh Ratan, Martin D. McCarter et al. (17 authors)

Cancers2023-10-1010 citations

10.3390/cancers15204913

Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.

Xuefeng Wang, Tingyi Li, Vineeth Sukrithan, Aakrosh Ratan, Martin D. McCarter et al. (15 authors)

Journal of Clinical Oncology2023-06-012 citations

10.1200/jco.2023.41.16_suppl.2617

1147 Differences in co-expression of T cell co-inhibitory and co-stimulatory molecules with PD1 across different human cancers

Ahmad A. Tarhini, Dale J. Hedges, Aik Choon Tan, Paulo C. Rodrı́guez, Vineeth Sukrithan et al. (17 authors)

Regular and Young Investigator Award Abstracts2022-11-011 citations

10.1136/jitc-2022-sitc2022.1147

1279 A novel graphical deep neural network learning approach utilizing molecular data for optimizing patient selection for treatment with immune checkpoint inhibitors: An ORIEN pan-cancer study

Issam El Naqa, Payman Ghasemi, Aik Choon Tan, James Chen, Aakrosh Ratan et al. (17 authors)

Regular and Young Investigator Award Abstracts2022-11-01

10.1136/jitc-2022-sitc2022.1279

54 Prognostic value of T cell immunoscore estimated from transcriptomic data in patients with advanced malignancies treated with immune checkpoint inhibitors

Ahmad A. Tarhini, Payman Ghasemi Saghand, Aik Choon Tan, James Chen, Aakrosh Ratan et al. (17 authors)

Regular and Young Investigator Award Abstracts2022-11-01

10.1136/jitc-2022-sitc2022.0054

Interventions

OTHERBiological specimen collection

Collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from patients with cancer or at risk of having cancer. This is not a treatment trial. It is a study designed to create a centralized data and tissue repository.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* 18 years of age and older. * Has a diagnosis of cancer or is suspected of having cancer. * Able to understand and sign the Informed Consent form directly. * Pregnant women are permitted to be enrolled.

Exclusion criteria

* Prisoners

Design outcomes

Primary

Measure	Time frame	Description
Amount of clinical patient demographic data collected for a repository linked to clinical data for long-term research use.	up to 20 years	Establish a longitudinal clinical data repository that will contain information about patient demographics collected via surveys and questionnaires.
Amount of clinical patient medical treatment and outcome data collected via medical histories for long-term research use	up to 20 years	Establish a longitudinal clinical data repository that will contain information about medical treatments and patient outcomes collected via medical chart review and patient medical histories.
Number of biospecimens collected for a tissue repository linked to clinical data for long-term research use	up to 20 years	Establish a longitudinal tissue repository that will contain tissues (blood, tumor tissue) and other biological samples and associated clinical data collected from consenting patients.

Countries

United States

Contacts

Primary ContactChristine Serway, PhD

CSerway@salud.unm.edu505-272-2412

Backup ContactEllen Wojcik, MBA-HCM

ewojcik@salud.unm.edu

Outcome results

None listed

Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

Conditions

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Countries

Contacts

Outcome results